Infusion Therapy Site of Care Optimization
Customize your policy alerts
Sign up for Peach State Health Plan Policy GA.PMN.34 alerts
Get alerted when Policy GA.PMN.34 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria and approval requirements for outpatient intravenous or injectable specialty infusion therapy and guidance for redirecting site of care among hospital outpatient, ambulatory infusion centers, offices, pharmacies, and home settings for Peach State Health Plan members.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial Approval Criteria
Covered when ALL of the following are met for inpatient outpatient or non-hospital outpatient infusion:
Provider must submit documentation (office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.
See subcriteria a–e for acceptable justifications to authorize higher-acuity site of care.
Non‑qualifying examples include trypanophobia, pediatrics, preference/convenience, frequent laboratory monitoring, and continuation of services from a previous plan.
Continued Approval
For continued approval:
Approval duration: up to one year or length of drug approval.
Per-code site-of-care coverage notes
Coverage and site-of-care guidance tied to specific J- and Q-codes with explicit exclusions or exemptions
Refer to the appendix/code table for the full list of J‑ and Q‑codes and their per‑code site/exemption notes.
Non-qualifying examples for justifying transfer of care from home to a higher-acuity outpatient/hospital setting include situations where the concern is trypanophobia (fear of needles), routine pediatrics care, patient preference or convenience, need for frequent laboratory monitoring, or merely continuation of services from a previous Plan. These items do not, by themselves, establish the medical necessity for a higher-intensity site of care.
Certain products and billing codes are explicitly identified with policy-level exclusions or with excluded indications. Examples shown in the code tables include entries marked as excluded (for example, portions of the J9217 and Q5107 listings) and agents with specified excluded indications such as ophthalmic indications excluded for some bevacizumab Q-codes. Providers should consult the per-code entries in the drug list for code-specific exclusion or exemption language when submitting authorization requests.
This clinical policy governs site-of-care determinations for Peach State Health Plan; however, applicable state legislation and regulatory requirements take precedence where there is a conflict. Providers must follow any state-specific mandates that supersede this policy in their jurisdiction.
Requests for outpatient IV or injectable therapy that do not meet the policy's initial approval criteria should be arranged in a less intensive site of care. The policy specifically directs that such services be provided in an alternate, less intensive site of care rather than authorizing the requested outpatient hospital or similarly higher-acuity setting unless there is documentation meeting initial-approval conditions (for example: no home infusion provider available, FDA-required administration setting, initial dose/restart after a 6-month disruption, documented health risk for home, or severe adverse events).
Codes and Coding Guidance
| J0129 | Abatacept / Orencia |
| J0172 | Aducanumab-Avwa / Aduhelm |
| J0180 | agalsidase beta / Fabrazyme |
| J0202 | alemtuzumab / Lemtrada |
| J0218 | Olipudase Alfa / Xenopozyme |
| J0221 | Avalglucosidase alfa-ngpt / Nexviazyme / Lumizyme |
| J0222 | patisiran / Onpattro |
| J0223 | givosiran / Givlaari |
| J0224 | lumasiran / Oxlumo |
| J0225 | vutrisiran / Amvuttra |
| J1576 | Listed in drug list (multiple mappings shown in document) |
| J1602 | Listed in drug list |
| J1626 | Listed in drug list |
| J1628 | Listed in drug list |
| J1740 | Listed in drug list |
| J1743 | Listed in drug list |
| J1744 | Listed in drug list |
| J1745 | Listed in drug list |
| J1786 | Listed in drug list |
| J1823 | Listed in drug list |
Provider Responsibilities and Authorization Requirements
Prior authorization required with clinical documentation
Prior authorization is required for outpatient hospital or non-hospital outpatient administration of IV or injectable therapy. Submit clinical documentation demonstrating the member meets the initial approval criteria (see Initial Approval Criteria) when requesting authorization for infusion in these settings.
- Documentation examples: office chart notes, lab results, other clinical information showing criteria are met.
Code-level site-of-care notes, exclusions, and exemptions — check per code
Many listed J- and Q-codes include site-of-care notes, with some codes explicitly excluded or having specific exemptions (e.g., maintenance, concurrent chemotherapy exemption, ophthalmic indications excluded, '1st visit in AIS'). Verify code-specific site guidance when requesting authorization.
Coverage decisions may require prior authorization per Health Plan
Coverage decisions and benefit administration are subject to the Health Plan's terms and may require prior authorization per the plan's administrative policies and procedures; follow plan documents when requesting coverage.
- The clinical policy is a guide to medical necessity but does not guarantee payment; check evidence of coverage, contracts, and applicable state/federal requirements.
Short-duration approval for initial dose or restart with transition plan
Initial administration or restart after a ≥6-month disruption may be authorized for a short duration (example: ~4 weeks) only if the provider requests the initial visit and documents a plan to transition continued administration to home infusion or an ambulatory infusion suite (AIS).
- Provider must submit the request for the initial visit including the plan for continued home or AIS administration.
Follow per-agent site-of-care flow notes (maintenance, exemptions, AIS first visit)
Certain agents include site-related flow notes (e.g., 'maintenance', 'concurrent chemotherapy is an exemption', '1st visit in AIS') that indicate permitted site-of-care pathways rather than classical step edits; apply these per-agent conditions when planning site of administration.
- Use the per-code table to determine if maintenance therapy, concurrent chemotherapy exemptions, or '1st visit in AIS' apply for the requested agent.
Include code-specific site justification and duration in request
Per the document's per-code entries and tables, providers should follow code-specific site guidance and include any required site justification and duration (for example, initial-visit short-duration approvals) when submitting requests.
- Include code(s) being requested and reference the per-code note (e.g., maintenance, exemption for concurrent chemotherapy, ophthalmic exclusion, '1st visit in AIS').
Submit supporting clinical documentation with authorization request
Providers must submit documentation (office chart notes, lab results, infusion records, or other clinical information) supporting that the member meets all approval criteria when requesting authorization.
- Include clinical evidence supporting any claimed reasons for higher-acuity site (no home infusion provider, contraindication to home/AIS, severe prior adverse events, etc.).
Document dosing per FDA label or manufacturer's package insert
Dosing and administration must follow the FDA approval or the manufacturer's package insert; reference the FDA label or package insert for specific dosing when documenting the request.
- Use the manufacturer's prescribing information as the authoritative source for dose and administration details included in the request.
Provide documentation consistent with clinical policy and plan coverage rules
Follow this clinical policy as a guide to medical necessity and submit documentation supporting medical necessity per the Health Plan's coverage documents and applicable laws when requesting authorization.
- Ensure submitted documentation aligns with plan terms, exclusions, and state/federal requirements referenced by the Health Plan.
Risk of denial for site-of-care mismatch — provide in less intensive setting if criteria not met
Requests for outpatient IV or injectable therapy that do not meet the Initial Approval Criteria should be provided in a less intensive alternate site of care; authorization for the requested higher-acuity site may be denied.
- Non-qualifying examples (e.g., preference/convenience, trypanophobia, pediatrics, frequent lab monitoring, continuation from prior plan) do not justify higher-acuity site.
Verify code-level exclusions and exemptions before requesting authorization
Certain J- and Q-codes are explicitly excluded or have specified exemptions noted in the per-code table; verify code-level exclusions or exemptions before submitting a request to avoid inappropriate authorization attempts.
Denial risk if request does not meet policy, benefit terms, exclusions, or legal requirements
Requests or claims may be denied if they do not meet the clinical policy, the Health Plan's benefit terms, or applicable exclusions, limitations, and regulatory requirements; ensure all elements of medical necessity and coverage are documented.
- Denials can result from failure to meet criteria, benefit exclusions, code-level exclusions, or conflicts with state/federal law or plan administrative policies.
Background and Scope
Specialty infusion therapy comprises intravenous or injectable administration of complex or chronic therapies that often require monitoring, specialized equipment, or trained personnel. Site-of-care optimization seeks to redirect administration and/or dispensing from higher-intensity outpatient facilities (such as hospital outpatient departments or community offices) to lower-cost, clinically appropriate settings (including home, ambulatory infusion centers/suites, or pharmacy) when safe and feasible. Authorization for higher-acuity sites is limited to circumstances that meet the policy's predefined criteria (for example, initial dose or restart after a 6-month disruption, absence of an available home infusion provider, FDA-required administration setting, significant physical or behavioral impairments that make home care unsafe, or severe, treatment-limiting adverse events).
Definitions and Key Terms
Initial Therapy — Medical Necessity
Initial Therapy
Initial therapy conditions that may require outpatient/hospital administration
Plan/intent to transition to home infusion or AIS is required; this is a limited, short duration authorization.
Such events may justify a higher‑acuity site of care.
These are illustrative examples, not exhaustive.
Continuation Therapy — Ongoing Approval Rules
Continuation Therapy
Rules for continued therapy approvals and reassessment of site of care
Approval duration: up to one year or length of drug approval.
Transition Plan and Step-Therapy Intent
| Step | Condition | Required Provider Action | Planned Transition / Duration |
|---|---|---|---|
| 1 | Initial administration or restart after ≥6-month disruption | Submit request for initial visit and clinical documentation supporting need for outpatient hospital/office administration | Short duration (e.g., ~4 weeks) with documented plan to transition to home infusion or ambulatory infusion suite (AIS) |
Site-of-Care Settings and Determinations
Site-of-care categories and example POS codes
Site of care categories include home, office, ambulatory infusion center/AIS, and hospital outpatient; Place of Service codes are provided in the policy for context (examples: home = POS 12, office = POS 11, hospital outpatient = POS 19 or 22, AIS = POS 24 or 11).
- Home — Place of Service Code 12
- Office — Place of Service Code 11
- Hospital outpatient — Place of Service Codes 19 or 22
- Ambulatory infusion center / AIS — Place of Service Code 24 or 11
Agent-specific site-of-care exclusions & exemptions
Many agents have site-of-care notes; some agents or codes are excluded from this policy, while others carry exemptions such as concurrent chemotherapy, ophthalmic indications excluded, or '1st visit in AIS'.
Home/site determinations must follow state law
Site-of-care determinations in this policy must comply with applicable state legislation and regulatory requirements, which take precedence when they conflict with the policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.